Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Roniciclib

Generic Name: Roniciclib

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₁F_₃N_₄O_₃S

CAS Number: 1223498-69-8

Unique Ingredient Identifier: 0W9Q8U337A

Overview

Roniciclib has been investigated for the treatment of Small Cell Lung Carcinoma.

Background

Roniciclib has been investigated for the treatment of Small Cell Lung Carcinoma.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors

Phase 2

Withdrawn

Posted: 2016/01/15

Sponsor:Dana-Farber Cancer I...

ID:NCT02656849

Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study

Phase 1

Completed

Posted: 2015/05/29

Sponsor:Bayer

ID:NCT02457351

Roniciclib Mass Balance Study

Phase 1

Completed

Posted: 2015/03/17

Sponsor:Bayer

ID:NCT02390154

RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer

Phase 2

Terminated

Posted: 2014/06/11

Sponsor:Bayer

ID:NCT02161419

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)

Phase 1

Terminated

Posted: 2012/04/09

Sponsor:Bayer

ID:NCT01573338

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy

Drug Development Updates

Roniciclib

Overview

Background

Indication

Associated Conditions

Clinical Trials

FDA Approved Products

Singapore Approved Products

Related News

CDK1 and TDP1 Inhibition Synergistically Overcomes Cancer Drug Resistance

Drug Development Updates